Literature DB >> 8417802

Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats.

B J de Smet1, J P de Boer, J Agterberg, G Rigter, W K Bleeker, C E Hack.   

Abstract

C1-inhibitor is the only known inhibitor of the classical pathway of complement and the major inhibitor of the contact pathway of coagulation. Like other serine proteinase inhibitors, C1-inhibitor can exist in three conformations, ie, the native, the proteinase-complexed, and the proteolytically inactivated form. Here we studied the plasma elimination kinetics of these three forms of human C1-inhibitor in rats. The clearance of the complexed form of C1-inhibitor appeared to be the most rapid and depended in part on the proteinase involved (observed plasma t1/2 was 20 minutes for C1s-C1-inhibitor, 32 minutes for kallikrein-C1-inhibitor, and 47 minutes for beta XIIa-C1-inhibitor), whereas that of native C1-inhibitor was the slowest (observed plasma t1/2 4.5 hours). Inactivated C1-inhibitor was cleared with an apparent plasma t1/2 of 1.6 hours. Thus, the short plasma t1/2 of complexed relative to native C1-inhibitor explains why in patients only low concentrations of C1-inhibitor complexes may be observed despite activation of the contact and/or complement systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417802

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury.

Authors:  Valeria Ramaglia; Ruud Wolterman; Maryla de Kok; Miriam Ann Vigar; Ineke Wagenaar-Bos; Rosalind Helen Mary King; Brian Paul Morgan; Frank Baas
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

3.  Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.

Authors:  Jan K Jensen; Klavs Dolmer; Peter G W Gettins
Journal:  J Biol Chem       Date:  2009-05-13       Impact factor: 5.157

4.  Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model.

Authors:  B H M Heijnen; I H Straatsburg; N D Padilla; G J Van Mierlo; C E Hack; T M Van Gulik
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

5.  Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis.

Authors:  H Yamaguchi; H Weidenbach; H Lührs; M M Lerch; G Dickneite; G Adler
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

6.  DNA and factor VII-activating protease protect against the cytotoxicity of histones.

Authors:  Gerben Marsman; Helen von Richthofen; Ingrid Bulder; Florea Lupu; Jan Hazelzet; Brenda M Luken; Sacha Zeerleder
Journal:  Blood Adv       Date:  2017-11-30

Review 7.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.

Authors:  M Levi; H ten Cate; K A Bauer; T van der Poll; T S Edgington; H R Büller; S J van Deventer; C E Hack; J W ten Cate; R D Rosenberg
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Early treatment with C1 esterase inhibitor improves weight but not memory deficits in a rat model of status epilepticus.

Authors:  Nicole D Schartz; Alexandra L Sommer; Samantha A Colin; Loyda B Mendez; Amy L Brewster
Journal:  Physiol Behav       Date:  2019-10-16

10.  Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients.

Authors:  Esther J Nossent; Alex R Schuurman; Tom D Y Reijnders; Anno Saris; Ilse Jongerius; Siebe G Blok; Heder de Vries; JanWillem Duitman; Anton Vonk Noordegraaf; Lilian J Meijboom; René Lutter; Leo Heunks; Harm Jan Bogaard; Tom van der Poll
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.